Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.47 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933678 | 0.85 | CHEK2 (0.45) | PLK1USP7MAPK14CHEK2HDAC2 | |
| SCHEMBL13933743 | 0.85 | RARB (0.34) | PLK1USP7MAPK14SMN1; SMN2 | |
| SCHEMBL3103361 | 0.82 | RPS6KA3 (0.47) | PLK1USP7MAPK14CHEK2HDAC2 | |
| SCHEMBL3104996 | 0.80 | PLK1 (0.46) | PLK1MAPK14CHEK2HDAC2HDAC8 | |
| SCHEMBL13933773 | 0.76 | EP300 (0.43) | PLK1USP7MAPK14CHEK2HTT | |
| SCHEMBL13175559 | 0.76 | PLK1 (0.55) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL29925407 | 0.73 | PLK1 (0.56) | PLK1USP7HDAC2HDAC8HDAC6 | |
| SCHEMBL3110462 | 0.71 | CHEK2 (0.41) | PLK1USP7CHEK2HDAC2HDAC8 | |
| SCHEMBL31495814 | 0.71 | PLAU (0.46) | PLK1HDAC2HDAC8HDAC6CA2 | |
| SCHEMBL18781295 | 0.71 | PLK1 (0.56) | PLK1HDAC2HDAC8HDAC6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, IGFBP1, IRS1 | PLK1 676/4885USP7 3770/4885MAPK14 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.